15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Tumor cells, which undergo Epithelial-mesenchymal transition (EMT) acquire increased capacities of proliferation, invasion and have the ability to generate metastases by escaping the immune system during their systemic migration. To escape the immune system, cancer cells may induce tolerance or resist elimination by immune effectors via multiple mechanisms and we hypothesized that EMT may control the expression of immune checkpoint inhibitors, then promoting immune evasion. PD-L1 (programmed cell death ligand 1) but not PD-L2 nor Galectin 9 or Death receptor (DR4, DR5 and Fas) and ligands (FasL and TRAIL) expression was up-regulated during cytokine-driven EMT in a reversible manner. Moreover PD-L1 is overexpressed in VIMENTIN positive NSCLC tissues. We also demonstrated that the expression of PD-L1 required both TNFα and TGFβ1. Indeed, TGFβ1 decreased DNMT1 content and that resulted in PD-L1 promoter demethylation whereas TNFα induced the NF-κB pathway that promoted expression of demethylated PD-L1 promoter.

          Related collections

          Author and article information

          Journal
          Oncoimmunology
          Oncoimmunology
          KONI
          koni20
          Oncoimmunology
          Taylor & Francis
          2162-4011
          2162-402X
          2018
          1 February 2018
          : 7
          : 5
          : e1423170
          Affiliations
          [a ] Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique , F-25000, Besançon, France
          [b ] University Hospital of Besançon, Medical Oncology Department, Besançon , France
          [c ] Clinical Investigation center-Biotherapy 1431 , Besançon, France
          [d ] INSERM unit S1232, University of Nantes , Nantes, France
          [e ] Institut de cancérologie de l'Ouest , Nantes, France
          [f ] member of the REpiCGO (Cancéropole Grand-Ouest, France) and EpiSAVMEN (Région Pays de la Loire, France) networks , France
          [g ] EPIGENExp (EPIgenetics and GENe EXPression Technical Platform) , Besançon, France
          [h ] Laboratory of Experimental Pathology, GIGA-Cancer, University of Liege , Liege, Belgium
          Author notes
          CONTACT C. Borg christophe.borg@ 123456efs.sante.fr 8, rue du Docteur Jean-François-Xavier Girod BP 1937 25020 Besançon Cedex France
          E. Hervouet France.eric.hervouet@ 123456univ-fcomte.fr 16 route de Gray, 25360 Besançon cedex

          Supplemental data for this article can be accessed on the publisher's website.

          [1]

          Present address: EA3181 University of Bourgogne Franche Comté, Besançon.

          [*]

          These authors contributed equally to this work.

          Article
          PMC5927541 PMC5927541 5927541 1423170
          10.1080/2162402X.2017.1423170
          5927541
          29721376
          9d21f7bb-4f87-4adb-965d-5132bfefbece
          © 2018 Taylor & Francis Group, LLC
          History
          : 28 September 2017
          : 21 December 2017
          : 22 December 2017
          Page count
          Figures: 7, Tables: 0, Equations: 0, References: 55, Pages: 13
          Funding
          Funded by: Ligue Contre le Cancer 10.13039/501100004099
          Award ID: 001AC.2015
          Funded by: ANR
          Award ID: ANR-11-LABX-0016-01
          This work was supported by the Ligue Contre le Cancer (001AC.2015), LabeX IGO, University of Franche-Comté, Région Franche-Comté and the ANR(ANR-11-LABX-0016-01).
          Categories
          Original Research

          PD-L1,NF-kB,lung cancer, cancer,epithelial-mesenchymal transition,DNA methylation,death receptors

          Comments

          Comment on this article